128 related articles for article (PubMed ID: 37443453)
1. Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1.
Zeng Z; Lin C; Zhang MC; Kossinna P; Wang P; Cao D; Wang J; Xu M; Wang X; Li Q; Xu X; Yang H; Zhu S; Liu GR; Xie K; Yang J; Luo Y; Wang Y; Zhang XH; Lin J; Chen H; Liu SL; Liu H
Phytother Res; 2023 Oct; 37(10):4722-4739. PubMed ID: 37443453
[TBL] [Abstract][Full Text] [Related]
2. Enterolactone has stronger effects than enterodiol on ovarian cancer.
Liu H; Liu J; Wang S; Zeng Z; Li T; Liu Y; Mastriani E; Li QH; Bao HX; Zhou YJ; Wang X; Hu S; Gao S; Qi Y; Shen Z; Wang H; Yu M; Gao T; Johnston RN; Liu SL
J Ovarian Res; 2017 Jul; 10(1):49. PubMed ID: 28738876
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of hsa-miR-214-3p.
Wang C; Qi S; Xie C; Li C; Wang P; Liu D
J Gynecol Oncol; 2018 Nov; 29(6):e99. PubMed ID: 30207107
[TBL] [Abstract][Full Text] [Related]
4. Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model.
Canese R; Palombelli G; Chirico M; Sestili P; Bagnoli M; Canevari S; Mezzanzanica D; Podo F; Iorio E
NMR Biomed; 2019 Oct; 32(10):e4016. PubMed ID: 30375088
[TBL] [Abstract][Full Text] [Related]
5. Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
Matuszewska K; Ten Kortenaar S; Pereira M; Santry LA; Petrik D; Lo KM; Bridle BW; Wootton SK; Lawler J; Petrik J
Gynecol Oncol; 2022 Jan; 164(1):154-169. PubMed ID: 34799137
[TBL] [Abstract][Full Text] [Related]
6. IGFBP3 inhibits angiogenesis through intracellular regulation of THBS1 expression.
Shih HJ; Chen CL; Torng PL
Am J Cancer Res; 2020; 10(6):1728-1744. PubMed ID: 32642286
[TBL] [Abstract][Full Text] [Related]
7. Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota.
Lin C; Zeng Z; Lin Y; Wang P; Cao D; Xie K; Luo Y; Yang H; Yang J; Wang W; Luo L; Lin H; Chen H; Zhao Y; Shi Y; Gao Z; Liu H; Liu SL
Phytomedicine; 2022 Nov; 106():154401. PubMed ID: 36029647
[TBL] [Abstract][Full Text] [Related]
8. CircCERS6 Suppresses the Development of Epithelial Ovarian Cancer Through Mediating miR-630/RASSF8.
Li X; Jiang X; Lu J; Lin Y; Jiang L; Li Y; Wan F; Wang C
Biochem Genet; 2022 Dec; 60(6):2611-2629. PubMed ID: 35676548
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Newhouse R; Nelissen E; El-Shakankery KH; Rogozińska E; Bain E; Veiga S; Morrison J
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD006910. PubMed ID: 37407274
[TBL] [Abstract][Full Text] [Related]
11. Migration-inducing gene 7 promotes tumorigenesis and angiogenesis and independently predicts poor prognosis of epithelial ovarian cancer.
Huang B; Yin M; Li X; Cao G; Qi J; Lou G; Sheng S; Kou J; Chen K; Yu B
Oncotarget; 2016 May; 7(19):27552-66. PubMed ID: 27050277
[TBL] [Abstract][Full Text] [Related]
12. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
Erriquez J; Olivero M; Mittica G; Scalzo MS; Vaira M; De Simone M; Ponzone R; Katsaros D; Aglietta M; Calogero R; Di Renzo MF; Valabrega G
Oncotarget; 2016 May; 7(18):26181-91. PubMed ID: 27027433
[TBL] [Abstract][Full Text] [Related]
13. MiR-19a enhances cell proliferation, migration, and invasiveness through enhancing lymphangiogenesis by targeting thrombospondin-1 in colorectal cancer.
Yin Q; Wang PP; Peng R; Zhou H
Biochem Cell Biol; 2019 Dec; 97(6):731-739. PubMed ID: 31199884
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase A receptor (trkA): a potential marker in epithelial ovarian cancer.
Tapia V; Gabler F; Muñoz M; Yazigi R; Paredes A; Selman A; Vega M; Romero C
Gynecol Oncol; 2011 Apr; 121(1):13-23. PubMed ID: 21236475
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR-155-5p.
Tong L; Ao Y; Zhang H; Wang K; Wang Y; Ma Q
Cancer Med; 2019 Aug; 8(10):4782-4791. PubMed ID: 31250987
[TBL] [Abstract][Full Text] [Related]
17. Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing miR-222-3p transcription and upregulating PDCD10.
Fan L; Lei H; Zhang S; Peng Y; Fu C; Shu G; Yin G
Theranostics; 2020; 10(13):5895-5913. PubMed ID: 32483426
[No Abstract] [Full Text] [Related]
18. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Stone RL; Baggerly KA; Armaiz-Pena GN; Kang Y; Sanguino AM; Thanapprapasr D; Dalton HJ; Bottsford-Miller J; Zand B; Akbani R; Diao L; Nick AM; DeGeest K; Lopez-Berestein G; Coleman RL; Lutgendorf S; Sood AK
Cancer Biol Ther; 2014 Jul; 15(7):919-29. PubMed ID: 24755674
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.
Momeny M; Sabourinejad Z; Zarrinrad G; Moghaddaskho F; Eyvani H; Yousefi H; Mirshahvaladi S; Poursani EM; Barghi F; Poursheikhani A; Dardaei L; Bashash D; Ghazi-Khansari M; Tavangar SM; Dehpour AR; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Sci Rep; 2017 Apr; 7():45954. PubMed ID: 28383032
[TBL] [Abstract][Full Text] [Related]
20. NGF/TRKA Decrease miR-145-5p Levels in Epithelial Ovarian Cancer Cells.
Garrido MP; Torres I; Avila A; Chnaiderman J; Valenzuela-Valderrama M; Aramburo J; Oróstica L; Durán-Jara E; Lobos-Gonzalez L; Romero C
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
